DOI: 10.24911/JBCGenetics.183-1733834270

EDITORIAL

Gene therapy for rare genetic disorders: transformative progress, challenges, and future prospects

Muhammad Umair[1]

The emergence of gene therapy has heralded a revolutionary era in the medical domain, especially for the treatment of rare genetic disorders. These conditions, stemming from mutations in individual genes, frequently result in severe health issues with few treatment options. For years, the outlook for individuals with inherited rare diseases was dire, as conventional therapies failed to address most of these disorders. However, recent progress in gene therapy is unlocking new possibilities for curing or alleviating the impact of these disorders by directly modifying the genetic material at the root of the disease. This editorial delves into the importance, constraints, and future prospects of gene therapy in the context of inherited rare diseases, highlighting its role as a pioneering force in personalized medical care (1).

Significance of Gene Therapy

Gene therapy operates on the concept of modifying a patient's genome to rectify or counteract a faulty gene responsible for a disease. This can involve inserting a functional gene, repairing a defective one, or silencing a disease gene. For rare genetic disorders, where the specific mutations are usually well understood, gene therapy offers the potential for a cure by targeting the underlying cause rather than just managing symptoms.

In diseases such as spinal muscular atrophy (SMA), cystic fibrosis, Duchenne muscular dystrophy (DMD), and hemophilia, gene therapy has already produced transformative outcomes. The approval of Zolgensma for SMA - a typically fatal condition causing progressive muscle weakness in early childhood - marks a landmark achievement in gene therapy. By delivering a healthy copy of the *SMN1* gene via an adeno-associated viral (AAV) vector, Zolgensma has demonstrated its ability to halt disease progression and restore motor abilities in affected infants. Furthermore, gene therapy is pushing the boundaries of personalized medicine. It enables the development of medicine tailored to each patient's unique genetic mutation, making it an invaluable tool for rare diseases that are often poorly understood. The capacity to rectify genetic defects at the molecular level opens up novel treatment pathways that could dramatically improve the lives of millions affected by rare inherited conditions (2).

Limitations of Gene Therapy

Despite its promise, gene therapy for rare genetic disorders confronts several critical challenges that must be resolved before it can become a standard treatment option (3).

Delivery challenges

A major constraint of gene therapy is the delivery system. Effective gene editing or replacement requires a safe and efficient method for introducing therapeutic genetic material into the target cells. Viral vectors, such as AAV, are commonly used for gene transfer but have limitations, including the risk of immune reactions, unintended effects, and issues with sustained gene expression. Delivering therapeutic genes to certain tissues, such as the central nervous system or skeletal muscles, remains a significant obstacle.

Safety considerations

While gene therapy has advanced significantly, safety remains a top priority. The introduction of foreign genetic material can provoke immune responses that may reduce the therapy's effectiveness and cause serious side effects. The long-term safety of gene therapies is still under evaluation, and concerns about the potential for cancerous changes caused by introduced genes must be addressed. Ongoing research is focused on minimizing these risks, especially for patients receiving multiple gene therapy treatments.

Correspondence to: Muhammad Umair
*Medical Genomic Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences(KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia.
Email: umairmu@ngha.med.sa
Full list of author information is available at the end of the article.
Received: 10 December 20224 | **Accepted:** 12 December 2024

Cost implications

The high cost of gene therapy presents a substantial barrier to its widespread use. Treatments, such as Zolgensma and Luxturna, are extremely high and can reach millions of dollars. Even while these expenses may be justified by the long-term advantages and the possibility of treating deadly diseases, many patients and healthcare systems are restricted by the financial load, especially in low-income nations.

Future Directions

Gene therapy has undeniably become a revolutionary method for managing rare genetic disorders, infusing new hope in the lives of patients and their families who were diagnosed with incurable conditions. Recent advancements in treating diseases, such as SMA, hemophilia, and DMD, illustrate that gene therapy is not just a means to slow down the progression of these disorders but also a potential pathway to actual cures. Although these advances are encouraging, we must overcome significant challenges related to delivery systems, safety, efficacy, and cost (4).

The coming decade will be a pivotal time in addressing these challenges, with advances in vector development, gene-editing methods such as CRISPR-Cas9, and personalized medicine playing a key role in breaking down current barriers and expanding the use of gene therapy to a wider array of rare genetic conditions. Furthermore, joint initiatives, including regulatory agencies, academic research institutions, and the pharmaceutical industry, will be vital in developing more affordable and accessible treatments, ensuring that the advantages of gene therapy extend beyond a select few (3,4).

Conclusion

In the larger context, gene therapy represents a significant advancement for precision medicine as a whole as well as for the treatment of rare genetic diseases. Gene therapy has the potential to revolutionize genetic healthcare by becoming a key component in the treatment of hereditary diseases as our understanding and technology breakthroughs progress.

Author details

Muhammad Umair[1]

1. Medical Genomic Research Department, King Abdullah International Medical Research Center (KAIMRC), King Saud Bin Abdulaziz University for Health Sciences(KSAU-HS), Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia

References

1. Kirschner J, Cathomen T. Gene therapy for monogenic inherited disorders. Dtsch Arztebl Int. 2020;117(51-52):878–85. https://doi.org/10.3238/arztebl.2020.0878
2. Parambi DGT, Alharbi KS, Kumar R, Harilal S, Batiha GE, Cruz-Martins N, et al. Gene therapy approach with an emphasis on growth factors: theoretical and clinical outcomes in neurodegenerative diseases. Mol Neurobiol. 2022;59(1):191–233. https://doi.org/10.1007/s12035-021-02555-y
3. Sioson VA, Kim M, Joo J. Challenges in delivery systems for CRISPR-based genome editing and opportunities of nanomedicine. Biomed Eng Lett. 2021;11(3):217–33. https://doi.org/10.1007/s13534-021-00199-4
4. Papaioannou I, Owen JS, Yáñez-Muñoz RJ. Clinical applications of gene therapy for rare diseases: a review. Int J Exp Pathol. 2023;104(4):154–76. https://doi.org/10.1111/iep.12478